✦ LIBER ✦

Darbepoetin-α every 2 weeks promising for anaemic patients with kidney disorders

Book ID: 120849599
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2006
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200615470-00026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

113: De Novo Every-Other-Week (Q2W) Darb

113: De Novo Every-Other-Week (Q2W) Darbepoetin Alfa Administration in Patients with Chronic Kidney Disease (CKD): Hemoglobin (HB) Levels on Initiation of Therapy

✍ Reshma Kewalramani; Chao-Yin Chen; Preston Klassen 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 185 KB

Evaluation of the US Oncology Network's

Evaluation of the US Oncology Network's Recommended Guidelines for Therapeutic Substitution with Darbepoetin alfa 200 μg Every 2 Weeks in Both Naïve Patients and Patients Switched from Epoetin alfa

✍ William A. Thames; Sandra L. Smith; Andrew C. Scheifele; Bin Yao; Suzana A. Giff 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB

Assessing symptom burden using the M. D.

Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia : Results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-α at a dose of 200 μg every 2 weeks

✍ Janice L. Gabrilove; Edith A. Perez; Dianne K. Tomita; Greg Rossi; Charles S. Cl 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 346 KB

## Abstract ## BACKGROUND. Patients with cancer who are receiving chemotherapy often experience chemotherapy‐induced anemia (CIA), which is associated with symptoms that reduce quality of life. The M. D. Anderson Symptom Inventory (MDASI) is a brief, self‐rating assessment scale that measures the